Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Safety Panel Urges New Entity To Oversee Japan Drug Approvals

This article was originally published in The Pink Sheet Daily

Executive Summary

The independent, neutral body would be charged with monitoring, inspecting and investigating MHLW, the Pharmaceutical and Medical Devices Agency and other government administrative functions.

You may also be interested in...



India Price Regulator Wants At Least Five Drug Makers Charged

India's regulator of drug prices has called for legal action against five pharmaceutical companies on charges they violated price controls. The National Pharmaceutical Pricing Authority said the companies collectively sold 39 specified pack sizes of different drugs without prior approval of the prices. The firms named were Alembic, Cadilla Healthcare, Medley Pharmaceuticals, Lupin and Wockhardt. The NPPA said it also is looking at nearly 30 other cases of alleged overcharges and is asking the firms involved to repay the excess amounts. It asked state governments to begin prosecution proceedings. (Click here for more

More Reform Eyed For Japan's OTC Deregulation

Japan's executive branch will urge the country's drug regulators to relax recently imposed limits on online sales of OTC products

More Reform Eyed For Japan's OTC Deregulation

Japan's executive branch will urge the country's drug regulators to relax recently imposed limits on online sales of OTC products

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069364

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel